The Rewilding And Regeneration Of The Luxury Adventure: Luca Franco, CEO and Founder of Luxury Frontiers. X
The Rewilding And Regeneration Of The Luxury Adventure: Luca Franco, CEO and Founder of Luxury Frontiers. May. 19th, 2021
Luca Franco is the Founder and CEO of Luxury Frontiers, a San Francisco/Johannesburg- based international firm specializing in design, development, and guest experience concepts for upmarket, light-on-earth hospitality structures ranging from tented camps to treetop suites.
Drawing on his passion for transformational travel, re-wilding, and entrepreneurship, Mr. Franco founded Luxury Frontiers in 2011 and has grown the firm with a multicultural team of designers, architects, and eco-resort experts to create truly experiential hospitality structures.
Gaensel Energy Group, Inc Announces Effective June 1, 2021, Our New Chief Executive Officer/President and Secretary/Treasurer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Gaensel Energy Group, Inc Announces, Effective June 1, 2021, Our New Chief Executive Officer/President and Secretary/Treasurer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Addex Therapeutics Ltd: Addex s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
important
2
1 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that dipraglurant was able to rescue long-term impairment of synaptic plasticity in two well validated models of dystonia. The data were published in the journal, Neuropharmacology, under the title Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models , by a team led by Antonio Pisani, MD, PhD, from the Department of Brain and Behavioral Sciences, University of Pavia, and Mondino Foundation, Pavia, Italy.